“We expect the establishment of the Korean subsidiary will aid the smooth supply of mRNA vaccines and allow for a more active engagement and communication with the Korean government, media, and academia.”

This was what Moderna had said on the 2nd to the invited media at a press conference. Moderna’s establishment of the Korean subsidiary had been the focus of all interest, that a US biotech that had gained nationwide fame in the COVID-19 pandemic will be establishing a subsidiary in Korea. Their establishment of a branch indicates that their plans do not end at selling COVID-19 vaccines in the area. It had also signed CMO agreements with Samsung Biologics for the fill&finish manufacturing of its vac